Global real‐world data on hemodiafiltration: An opportunity to complement clinical trial evidence

Hemodiafiltration (HDF) is a renal replacement therapy that utilizes both diffusive clearance and convective transport to achieve greater clearance of middle‐molecular‐weight solutes. Among other factors, important prerequisites for the implementation of HDF include access to high‐flux dialyzers, achievement of high blood flow rates, and availability of high volumes of sterile substitution/replacement fluids. Online hemodiafiltration (OL‐HDF) is an established kidney replacement therapy, frequently used in many countries. Although in the United States, some prerequisites (e.g., access to high‐flux dialyzers and achievement of high blood flow rates) for OL‐HDF treatment are readily available; however, a machine capable of generating the online solution for OL‐HDF is currently not available. As the clinical experience with HDF accumulates globally, it is worth examining the evidence for this kidney replacement therapy as used in routine clinical care. Such real‐world evidence is increasingly recognized as valuable by clinicians and may inform regulatory decisions. In this review, we will focus on emerging global real‐world data derived from routine clinical practices and examine how these data may complement those derived from clinical trials.